Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/53215
Type
ArticleCopyright
Open access
Collections
- IOC - Artigos de Periódicos [12500]
Metadata
Show full item record
PLATELET-LEUKOCYTE INTERACTIONS IN COVID-19: CONTRIBUTIONS TO HYPERCOAGULABILITY, INFLAMMATION, AND DISEASE SEVERITY
Affilliation
Universidade de Juiz de Fora. Departamento de Bioquímica. Laboratório de Imunotrombose. Juiz de Fora, MG, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil.
Abstract
A State of the Art lecture titled “Platelet-leukocyte
interactions in COVID-19:
Contributions to hypercoagulability, inflammation and disease severity” was presented
at the International Society for Thrombosis and Hemostasis (ISTH) congress in
2021. Severe coronavirus disease 2019 (COVID-19)
has been associated with a high
incidence of coagulopathy and thromboembolic events that contributes to disease
severity and poor outcomes. Therefore, understanding the mechanisms of COVID-19-
associated
hypercoagulability and thromboinflammation has gained great interest.
Here, we review the mechanisms involved in platelet activation and platelet interactions
with leukocytes during COVID-19.
We highlight recent evidence that platelet activation,
platelet-monocyte,
and platelet-neutrophil
interactions in COVID-19
support
pathological thromboinflammation, including in driving tissue factor expression and
NETosis, which have been associated with thromboembolic complication and poor
outcomes in critically ill patients. The contributions of platelet-leukocyte
interactions
to COVID-19
immunoregulation, inflammation, and hypercoagulability, as well as their
potential implications in disease severity and therapeutic strategies, will be discussed.
Finally, we summarize relevant new data on this topic presented during the 2021 ISTH
Congress.
Share